Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295060 | 0.92 | MAPK1 (0.44) | MAPK1GPR119ESR2GRM5GRM1 | |
| SCHEMBL17518353 | 0.89 | MAPT (0.46) | GPR119ESR2P2RX3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17518345 | 0.84 | P2RX3 (0.43) | MAPK1ESR2P2RX3NR1H2PARP1 | |
| SCHEMBL17518221 | 0.81 | P2RX3 (0.40) | MAPK1ESR2GRM5GRM1P2RX3 | |
| SCHEMBL29579608 | 0.81 | MAPT (0.48) | GPR119P2RX3ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22423970 | 0.79 | GPR119 (0.47) | GPR119 | |
| SCHEMBL13328820 | 0.78 | MAPK1 (0.41) | MAPK1ESR2P2RX3NR1H2PARP1 | |
| SCHEMBL22410804 | 0.77 | P2RX3 (0.44) | MAPK1GRM5GRM1P2RX3PARP1 | |
| SCHEMBL16005978 | 0.77 | ALDH1A1 (0.46) | MAPK1ESR2ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL31638196 | 0.75 | P2RX3 (0.41) | MAPK1ESR2P2RX3NR1H2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016024598-A1 | NOVEL TETRAHYDRO PYRIDOPYRIMIDINONE DERIVATIVE | 味の素株式会社 | 2016-02-18 | — | — | WO | disclosed |
| US-20150368242-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368242-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-12-24 | — | — | US | disclosed |
| WO-2015129845-A1 | NOVEL TETRAHYDRO PYRIDO PYRIMIDINONE DERIVATIVE | 味の素株式会社 | 2015-09-03 | — | — | WO | disclosed |
| WO-2014133134-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE | 味の素株式会社 (JP) | 2014-09-04 | — | — | WO | disclosed |
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232282-B2 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2398800-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010095767-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-08-26 | — | — | WO | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
| EP-2078719-A1 | COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093771-A1 | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same | GART, MGAT2, MGAT1 | MAPK1 1840/4885GPR119 4/4885ESR2 3969/4885 |
| US-20150368242-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE | MGAT2, MGAT1, MGAT3 | MAPK1 2101/4885GPR119 73/4885ESR2 3178/4885 |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | ABL1, JAK2, JAK1 | MAPK1 967/4885GPR119 1918/4885ESR2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.